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Introduction
AKU is an iconic disease in medicine, historically used 
by Archibald Garrod in his Croonian lectures of 1908, to 
demonstrate the theory behind “inborn errors of metabolism”. 
It was one of the first disorders in humans found to conform 
with the principles of Mendelian recessive inheritance.1 It is a 
hereditary disorder and results from absence of homogentisate 
1,2 dioxygenase (HGD), the enzyme, predominantly produced 
by hepatocytes in the liver and within the kidney, is responsible 
for the breakdown of HGA; an intermediate in the tyrosine 
degradation pathway (Fig. 1).2
Deficient HGD activity within the liver causes HGA levels to 
rise systemically. Large (gram) quantities of HGA are removed by 
urinary excretion on a daily basis.3 Other incidental observations 
of HGA in bodily fluids and tissues has been documented, based 
on the darkening of fluids or pathological deposition in tissues.4,5 
However, the removal of HGA by urinary excretion is not 
sufficient to completely remove it from bodily tissues and fluids.
Characteristic early clinical presentation is the observation that 
urine darkens on standing. This is because the HGA polymerizes 
but can also be observed upon the addition of alkali substances.2 
This is the only symptom seen in the pediatric age group.6 
Over time the HGA polymer is deposited within connective 
tissues, causing ochronosis (a darkening of collagenous tissues).7 
Long-term ochronosis results in the development of ochronotic 
osteoarthropathy, often misdiagnosed as early onset osteoarthritis 
(OA),2 unless observation of darkened urine has been seen before 
joint manifestations. Previous work has summarized the human 
disease, the genetics, and its manifestations.8
There is currently no approved cure for AKU. However, 
research surrounding the mechanism of disease progression 
has highlighted that HGA pigment deposition occurs within 
structurally intact cartilage. The research identified that 
ochronotic osteoarthropathy and subsequent joint failure appear 
to arise following initial changes in the calcified cartilage and 
subchondral bone becoming susceptible to damage following 
focal change. This has led to suggestions that there could be a 
large overlap between the pathogenesis of OA and ochronotic 
osteoarthropathy, increasing the potential avenues of research.9
Epidemiology
The worldwide prevalence of AKU is 1 case in 
250 000–1 000 000 births.2 So far, 950 AKU sufferers have 
been identified in 40 countries (Fig. 2).10,11 It is a condition that 
is reported to be more prevalent in Slovakia, the Dominican 
Republic, India, and Jordan. The highest prevalence is in Slovakia 
where up to 1 in 19 000 are affected.10 Analysis of the affected 
families revealed they typically live within isolated hamlets, 
leading to conclusions that the usually high incidence was 
predominantly due to the founder effect (loss of genetic variation) 
as a result of genetic isolation.12 Although difficult to perform 
with such a rare condition, there is also no genotype-phenotype 
correlation; all mutations lead to the development of ochronosis.13
Research is still ongoing to fully understand the mechanism 
of disease progression; literature suggests the reporting of new 
cases has increased due to a raised profile of features associated 
with the disease.10 However, even with the increase in reporting 
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alkaptonuria (aKU) is a rare disorder of autosomal recessive 
inheritance. it is caused by a mutation in a gene that results in the 
accumulation of homogentisic acid (HGa). Characteristically, 
the excess HGa means sufferers pass dark urine, which upon 
standing turns black. This is a feature present from birth. Over 
time patients develop other manifestations of aKU, due to 
deposition of HGa in collagenous tissues, namely ochronosis 
and ochronotic osteoarthropathy.
although this condition does not reduce life expectancy, 
it significantly affects quality of life. The natural history of 
this condition is becoming better understood, despite gaps 
in knowledge. Clinical assessment of the condition has also 
improved along with the development of a potentially disease-
modifying therapy. Furthermore, recent developments in 
aKU research have led to new understanding of the disease, 
and further study of the aKU arthropathy has the potential to 
influence therapy in the management of osteoarthritis.
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of new cases, the number of individuals documented as suffering 
from the disease is well below what would be expected based on 
the incidence.
Clinical Features
AKU has three distinct clinical features; homogentisic 
aciduria, ochronosis, and ochronotic osteoarthropathy.14-17 
Each feature presents at various stages in life, the earliest being 
detection of HGA in urine.18 The passing of black urine is 
the only manifestation of the condition known in pediatrics, 
leading to 21% of patients being diagnosed with AKU before 
1 year of age.2,6 Although newborn screening is not undertaken, 
incidental discoveries have been observed during other screening 
programs.19 HGA plasma levels in AKU sufferers range between 
0.018–0.165 mM in comparison to non-AKU sufferers plasma 
levels of 0.014–0.071 µM, a thousand fold difference.2,20 The 
darkening of urine occurs because the HGA pigment oxidizes 
to Benzoquinoneacetate (BQA), which forms a melanin-like 
polymer that slowly turns urine black.2
Ochronosis develops as the BQA accumulates both intra- and 
extra-cellularly in connective tissue. This feature is commonly 
observed in the third through to fifth decades of life. Typically 
the pigment is seen clearly in the eyes and ears of patients but is 
also present in bodily fluids, including perspiration, which often 
results in skin discoloration.21 Organs affected are: large joints, 
cardiovascular system, kidney, skin, and glands.4,7,22-24 Other 
manifestations include: renal, prostate, gall bladder, and salivary 
gland stones, ruptures of tendons and ligaments, osteopenia, and 
fractures.4,25-27
Cardiac manifestations of the disease 
are not uncommon. Aortic valve stenosis is 
a frequent finding, often requiring surgical 
replacement.23 It may be that mechanical 
forces play a key role in mediating ochronosis 
given that there appears to be little 
pigmentation in the venous component of 
the circulation compared with the arterial 
side.17 Interestingly, while HGD expression 
and HGA metabolism occur in the liver, 
there are no reports to demonstrate that 
these tissues—along with those of the 
pancreas, gastrointestinal, lymphoreticular, 
or endocrine organs—develop ochronosis.17
The development of ochronotic arthropathy 
is the result of deposition of the HGA 
polymer within hyaline articular cartilage. 
Pigmentation is widespread, with all tissues of 
the joint organ being affected (Table 1). The 
affected tissues often become weak, brittle, and 
prone to chipping, fracturing, and cracking, 
causing rapid joint degeneration, which means 
that patients can be left profoundly disabled at 
a young age.7 Although AKU does not affect 
longevity, it significantly affects quality of life 
due to these secondary pathologies.
Patients with ochronotic arthropathy usually present with 
lumbar pain as the initial joint manifestation. Larger weight bearing 
joints tend to be affected later in the progression of the condition.28 
Quite often this complaint is misdiagnosed as an early form of 
osteoarthritis (OA) or ankylosing spondylitis. The differences 
between the two conditions are summarized in Tables 2 and 3. It 
is interesting to note that the ossification of tissues in ochronosis 
is different from that observed in other forms of pathological 
ossification. This is because the ossification of tissues in ochronosis 
is seen with a variety of calcium crystals.29,30 Furthermore, 
biomechanical studies have shown that ochronotic cartilage 
calcification is harder than normal cartilage calcification.17,31,,32
History of AKU
Garrod’s use of AKU in the Croonian lectures brought the 
condition into the spotlight in 1908. Yet many descriptions of the 
triad of features associated with AKU date back long before this.2 
Documentation of the condition began in the 16th and 17th 
centuries.24 The earliest clinical case of AKU was found in the 
Egyptian mummy Harwa, which is believed to date back as far 
as 1500 BC.33 The name Alkaptonuria is derived from the Arabic 
word “alkali” (meaning alkali) and the Greek word meaning “to 
suck up oxygen greedily in alkali”.24 The name was created by 
Boedeker in 1859 after he discovered unusual reducing properties 
in the urine of a patient.14,15
Ochronosis was first described and named by Virchow in 
1866, because under microscopy the HGA pigment appeared to 
be ochre (yellow/brown) in color.34 In 1891 HGA was identified 
as the causative component and named so due to its close 
Figure  1. adapted from reference 3. The diagram illustrates the normal phenylalanine and 
tyrosine degradation pathway, enzymes involved and defects that can occur (highlighted blue). 
The metabolism of HGa occurs in the liver, and HGD is an enzyme expressed in this organ.
www.landesbioscience.com rare Diseases 3
structural relationship with gentisic acid, a derivative of benzoic 
acid.1,21,35,36 By 1995 the genetic defect was discovered, cloned, 
and mapped to chromosome 3q21-q23.22,37,38
Therapies
Many therapies have been tried. However, currently as there is 
no effective therapy, the management of AKU remains palliative 
and involves physiotherapy, joint replacement surgery, and pain 
control. Ascorbic acid (ASC), more commonly known as vitamin 
C, is an antioxidant believed to reduce the conversion of HGA to 
BQA via oxidation. However, investigation revealed that although 
ASC reduced the HGA to BQA conversion, it did not affect HGA 
urinary excretion.39 Furthermore, it was found to increase HGA 
production, contributing to the formation of renal oxalate stones. 
This is concerning, as AKU patients are already at high risk for 
developing renal calculi.40,41 An additional study highlighted 
that vitamin C is a co-factor for 4-hydroxyphenylpyruvate 
Figure 2. Taken from reference 11. The map illustrates the current number of aKU patients identified worldwide.
Table 1. Summarizes the location of HGa pigment deposition through all layers of an articulating joint. 
Tissue Areas of pigmentation
Bone intracellular
Cartilage intra- and extra-cellular
Synovium extracellular
Capsule intra- and extra-cellular
Ligament extra-cellular
Tendon intra- and extra-cellular
Bone has predominantly intracellular pigmentation, located in both osteocytes and osteoclasts. Mineralized bone matrix is resistant to pigmentation, it 
is thought that the mineral crystals located on bone collagen are protective against HGa and its subsequent binding and polymerization on the collagen 
fibers. The chondrocytes within cartilage show numerous intracellular deposits. Pigment deposition within the synovium appears to be caused by large 
fragments of ochronotic cartilage that have broken off from the articular surface and have embedded in the synovium.28 although ligaments show large 
extracellular deposits, little work has looked at the cellular components of ligaments. investigation into tendons has demonstrated both intra- and extra-
cellular pigmentation.25
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dioxygenase, which causes increased HGA production. In the 
cases of young infants there were profound increases in urinary 
levels of HGA, leading to conclusions that this is a highly 
unsuitable treatment.42
A low protein diet, although logical, is not sustainable in 
the long-term for many patients. Approximately 6% of dietary 
protein is degraded via the HGA pathway, and intensive 
supervision is required with younger patients, especially during 
growth periods.43,44 Also, regardless of restrictions on dietary 
intake of tyrosine, tissue catabolism is likely to contribute to 
raised HGA plasma levels within individuals with AKU. There is 
also evidence to suggest that liver transplantation is a successful 
way to eradicate HGA from the body.45 Many therapies have been 
trialed and are summarized in Table 4.
Other, more promising therapy includes a triketone herbicide, 
Nitisinone (NTBC), that inhibits 4-hydroxyphenylpyruvate, an 
enzyme involved in the conversion of hydroxyphenylpyruvate to 
HGA (Fig. 1). It significantly reduces urinary excretion of HGA 
in both murine models and humans.47-49 Initially approved by 
the Food and Drug Administration (FDA) for the treatment 
of hereditary tyrosinaemia type I (HT1), there are, however, 
known side effects, including elevated plasma tyrosine levels 
causing corneal irritation. This can be ameliorated by reducing 
dietary intake of tyrosine. Other serious adverse events associated 
with elevated plasma tyrosine levels include thrombocytopenia, 
leukopenia, and porphyria.49 However, complications of using 
this therapy are the development of hereditary tyrosinaemia type 
III (HT3) and rarely a deficiency of 4-hydroxyphenylpyruvate. 
These conditions cause neurological complications; tremor, 
ataxia, delayed development, and intellectual impairment.2,50
Enzyme replacement would be an ideal therapy for AKU, 
consisting of immediate replacement of HGD in the tyrosine 
degradation pathway. However, there are potentially fatal 
complications associated with this therapy. It is imperative that 
the HGD enzyme is delivered to the exact location of tyrosine 
metabolism within the hepatocytes of the liver. If not, spontaneous 
formation of succinylacetone (formed from the production of 
MAA and FAA in tyrosine metabolism) would occur, which is 
toxic and highly mutagenic. Build-up of this substance in the 
body and bloodstream would create complications more serious 
than the ochronosis of AKU.51
Models of AKU
Many spontaneous reports of AKU in animals have been 
documented: crab-eating macaque, chimpanzee, orangutan, 
Dalmatians, cattle, horses, dogs, and rabbits. All the reports 
identify the appearance of dark urine but rarely identify 
ochronosis or joint involvement.52-56 Early attempts to study 
AKU in animal models were undertaken by intraperitoneal or 
intravenous and intra-articular injection of HGA into rabbits.57 
The study demonstrated the damaging effects of HGA. Animals 
that received multiple injections exhibited darkening of urine 
along with ochronosis of joint tissues, and those injected with 
HGA via intraperitoneal or intravenous routes did not exhibit 
ochronosis.56 The first model study was made using rats fed on a 
diet of 8% l-tyrosine for at least a 9 month period. This appeared 
to induce ochronosis and osteoarthropathy.58
The first murine model of AKU was generated in 1994 and 
proved to be key in aiding to map the location of the HGD 
mutation to chromosome 16. The report stated that although 
the mice excreted high levels of urinary HGA, there was no 
evidence that they developed ochronosis or arthropathy. This was 
hypothesized to be the result of the endogenous production of 
ascorbic acid in the digestive tract of the mouse, thus inhibiting 
the polymerization of HGA.59
Other studies have developed murine models of AKU, also 
concluding that despite elevated levels of HGA, the mice did not 
Table 2. adapted from reference 21. The table shows the differences between peripheral ochronotic arthropathy and osteoarthritis.31
Peripheral Ochronotic Arthropathy vs. Osteoarthritis
Joint Involved Narrowing of Joint Space Osteophytosis
Ochronosis
Knees, shoulders +++
Hips, elbows and ankles ++
Sacroiliac Joints ±
Symmetric or asymmetric






Symmetric or asymmetric Present
+++, significant involvement; ++, some involvement; ±, little or no involvement
Table 3. adapted from reference 21. The table shows the radiographic differences between ankylosing spondylitis and ochronotic spondylarthropathy. 
Ochronotic spondylarthropathy vs. ankylosing spondylitis (radiographic features)
Ochronosis Ankylosing spondylitis
Calcification of intervertebral discs ++ ±
Syndesmophytes ± +++
Ossification of ligaments +++ +
erosion and fusion of sacroiliac joints ± +++
Osteoporotic vertebral bodies ++ +
+++, significant involvement; ++, some involvement; +, minimal involvement; ±, little or no involvement
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exhibit the typical phenotypic ochronosis observed in the human 
presentation. Hypotheses as to why this occurred, aside from the 
production of ascorbic acid in mice, have stated that the mice do 
not live long enough for ochronosis to occur and that urinary 
excretion is efficient so that tissues are not exposed to the high 
concentration of HGA as seen in humans.60,61 Other animal 
models have produced similar reports, although arguably not as 
reliable.54
Contrary to the above reports, Taylor et al. produced the 
first data of tissue ochronosis in a murine model. The data 
from this study demonstrated ochronosis in tissues and joints of 
mice with the AKU genotype, similar to the presentation seen 
in humans.62 This was a novel finding and has subsequently 
enabled better understanding of the molecular pathology of the 
condition.
In more recent murine models, initiation and progression of 
pigmentation has been documented. At 15 weeks, pigmentation 
is visible, suggesting that ochronosis begins at an early age. 
Furthermore, ochronosis was seen in all mice, and pigmentation 
of chondrocytes also increased with mouse age.48 These models, 
along with others, have been used to investigate the effects of 
NTBC. The trials have been successful and demonstrate the 
delayed progression of ochronosis after drug administration. The 
conclusions from these studies suggest beginning therapy at an 
early stage in the development of ochronosis results in a more 
beneficial outcome.48,61
Initial trials of low dose NTBC in two patients with AKU 
showed a 69% reduction in urinary HGA excretion. However, 
there was a significant elevation in plasma tyrosine levels, 
increasing the risk of corneal crystal formation, corneal epithelial 
damage, and photophobia.2 A larger scale trial of nine patients 
was performed and also discovered a 95% reduction in urinary 
HGA excretion but an 11-fold increase in plasma tyrosine over 
a four month period. Although the tyrosinaemia did not cause 
eye complications in these patients, this is a concern when 
considering the efficacy of NTBC as a therapy for AKU.3 A three 
year trial of NTBC performed on a cohort of 40 patients also 
demonstrated similar results.47
AKU as a Model of Osteoarthritis
The development of murine and in vitro models of AKU have 
enabled a better understanding of the pathophysiology involved 
in the progression of ochronosis and the related osteoarthropathy. 
So far, research has identified that HGA is present in healthy 
cartilage but only becomes susceptible to degeneration following 
focal change.9 The potential overlap between the pathogenesis 
of OA and ochronotic arthropathy has stemmed from a better 
understanding of the importance of subchondral bone in the 
pathogenesis of OA63,64 and determining factors that influence 
the integrity of articular cartilage: subchondral bone turnover, 
chondrocyte function, and biomechanical stresses, all of which 
are affected in the arthropathy of AKU.63,65 Furthermore, AKU 
has already been documented as causing premature OA and 
mimicking the typical disease process; this extreme phenotype of 
OA could provide insights into OA.66,67
Summary
It has been over 100 years since Garrod first described AKU as 
an “inborn error of metabolism”. Within this time, the causative 
molecule has been isolated and identified, the enzymatic defect 
located, and the genetic mutation mapped. Yet there is still no 
effective treatment for this iconic condition. Interest in AKU 
research has increased recently, generating hope that potential 
disease modifying therapy is within reach.
Furthermore, it appears that the arthropathy of AKU may 
have similarities to OA—not only in its presentation but also 
its pathogenesis—leading to speculation that it could prove a 
useful extreme phenotype in highlighting missing knowledge in 
understanding OA. This would not be the first time that a rare 
disease has brought more knowledge to a common condition. For 
Table 4. adapted from reference 44. information on current and future therapies available from references 5 and 46.
Treatment Summary
ascorbic acid efficacy unproven, increases HGa production, may exacerbate condition
Low protein diet efficacy in adults unproven, compliance difficult
Lifestyle counselling Underused, lack of evidence base
Physiotherapy Underused
Pain control widely used, incompletely effective
Organ replacement Unjustified for a condition with preserved lifespan
Palliative surgery effective but invasive
Liver transplant Not frequently used, lack of evidence base
reverse pigment binding Not yet available
HGa lowering therapy:
Nitisinone Not shown to alter outcomes, increases tyrosine
enzyme replacement Not yet available
Gene replacement Not yet available
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example in musculoskeletal conditions, the discovery of sclerostin 
and its importance in the Wnt signaling pathway, highlighted 
by the high bone mass phenotypes of those with van Buchem 
Disease (VBD), has led to therapies for osteoporosis.68,69
It is encouraging to consider that further research into this 
condition may contribute to the understanding and treatment of 
joint degeneration not only in AKU but also in OA.
Disclosure of Potential Conflicts of Interest
No potential conflict of interest was disclosed.
Acknowledgments
The authors would like to thank the AKU society, Rosetrees 
Trust, and University Hospitals of Morecambe Bay NHS 
Foundation trust for funding.
References
1. Garrod AE, Oxon MD. The incidence of 
alkaptonuria: a study in chemical individuality. 1902. 
Mol Med 1996; 2:274-82; PMID:8784780
2. Phornphutkul C, Introne WJ, Perry MB, Bernardini 
I, Murphey MD, Fitzpatrick DL, Anderson PD, 
Huizing M, Anikster Y, Gerber LH, et al. Natural 
history of alkaptonuria. N Engl J Med 2002; 
347:2111-21; PMID:12501223; http://dx.doi.
org/10.1056/NEJMoa021736
3. Suwannarat P, O’Brien K, Perry MB, Sebring N, 
Bernardini I, Kaiser-Kupfer MI, Rubin BI, Tsilou E, 
Gerber LH, Gahl WA. Use of nitisinone in patients 
with alkaptonuria. Metabolism 2005; 54:719-28; 
PMID:15931605; http://dx.doi.org/10.1016/j.
metabol.2004.12.017
4. Taylor AM, Wilson PJ, Ingrams DR, Helliwell 
TR, Gallagher JA, Ranganath LR. Calculi and 
intracellular ochronosis in the submandibular tissues 
from a patient with alkaptonuria. J Clin Pathol 
2010; 63:186-8; PMID:20154043; http://dx.doi.
org/10.1136/jcp.2009.071365
5. Garcia SF, Egbert B, Swetter SM. Hereditary 
ochronosis: hyperpigmented skin overlying 
cartilaginous structures. Cutis 1999; 63:337-8; 
PMID:10388955
6. Peker E, Yonden Z, Sogut S. From darkening urine 
to early diagnosis of alkaptonuria. Indian J Dermatol 
Venereol Leprol 2008; 74:700; PMID:19180686; 
http://dx.doi.org/10.4103/0378-6323.45142
7. Keller JM, Macaulay W, Nercessian OA, Jaffe IA. New 
developments in ochronosis: review of the literature. 
Rheumatol Int 2005; 25:81-5; PMID:15322814; 
http://dx.doi.org/10.1007/s00296-004-0498-1
8. Kraus VB. Rare osteoarthritis: Ochronosis, Kashin-
Beck disease and Mseleni joint disease. In: Hochberg 
MC, Smolen SJ, Weinblatt ME, Weisman MH, ed. 
Rheumatology. 5th ed. Philadelphia (PA): Mosby; 
2011 p1825-1837.
9. Taylor AM, Boyde A, Wilson PJ, Jarvis JC, Davidson 
JS, Hunt JA, Ranganath LR, Gallagher JA. The role 
of calcified cartilage and subchondral bone in the 
initiation and progression of ochronotic arthropathy 
in alkaptonuria. Arthritis Rheum 2011; 63:3887-
96; PMID:22127706; http://dx.doi.org/10.1002/
art.30606
10. Ranganath L, Taylor AM, Shenkin A, Fraser WD, 
Jarvis J, Gallagher JA, Sireau N. Identification of 
alkaptonuria in the general population: a United 
Kingdom experience describing the challenges, 
possible solutions and persistent barriers. J Inherit 
Metab Dis 2011; 34:723-30; PMID:21311977; 
http://dx.doi.org/10.1007/s10545-011-9282-z
11. Develop AKUre. 950 AKU patients [Internet]. 
Cambridge (UK): The AKU Society and the 
DevelopAKUre Consortium: c2014 [cited 15 May 
2013]. Available from: http://www.developakure.
eu/950-aku-patients/
12. Srsen S, Müller CR, Fregin A, Srsnova K. 
Alkaptonuria in Slovakia: thirty-two years of research 
on phenotype and genotype. Mol Genet Metab 
2002; 75:353-9; PMID:12051967; http://dx.doi.
org/10.1016/S1096-7192(02)00002-1
13. Vilboux T, Kayser M, Introne W, Suwannarat P, 
Bernardini I, Fischer R, O’Brien K, Kleta R, Huizing 
M, Gahl WA. Mutation spectrum of homogentisic 
acid oxidase (HGD) in alkaptonuria. Hum Mutat 
2009; 30:1611-9; PMID:19862842; http://dx.doi.
org/10.1002/humu.21120
14. Boedeker C. Ueber das Alcapton; ein neuer Beitrag 
zur Frage: Welche Stoffe des Hams kannen 
Kupferreduction bewirken? Ztschr f rat Med 1859; 
7:130.
15. Boedeker C. Das Alkapton; ein Beitrag zur 
Frage:Welche Stoffe des Harns Konnen aus einer 
alkalischen Kupferoxydlosung Kupferoxydul 
reduciren? Ann Chem Pharmacol 1861; 117:98; 
http://dx.doi.org/10.1002/jlac.18611170106
16. Gaines JJ Jr. The pathology of alkaptonuric ochronosis. 
Hum Pathol 1989; 20:40-6; PMID:2643557; http://
dx.doi.org/10.1016/0046-8177(89)90200-1
17. Helliwell TR, Gallagher JA, Ranganath L. 
Alkaptonuria--a review of surgical and autopsy 
pathology. Histopathology 2008; 53:503-12; 
PMID:18336562
18. Peker E, Yonden Z, Sogut S, Peker E, Yonden Z, 
Sogut S. From darkening of urine is the early sign of 
alkaptonuria. Indian J Dermatol Ve 2008; 74:705
19. Bradley DM. Screening for inherited metabolic 
disease in Wales using urine-impregnated filter paper. 
Arch Dis Child 1975; 50:264-8; PMID:1147666; 
http://dx.doi.org/10.1136/adc.50.4.264
20. Deutsch JC, Santhosh-Kumar CR, Deutsch J, 
Santhoshkumar C. Quantitation of homogentisic 
acid in normal human plasma. J Chromatogr B 
Biomed Appl 1996; 677:147-51; PMID:8925087; 
http://dx.doi.org/10.1016/0378-4347(95)00442-4
21. Klippel JH, Dieppe PA. Rheumatology - Volume Two. 
London, UK: Mosby, 1998.
22. Fernández-Cañón JM, Granadino B, Beltrán-Valero 
de Bernabé D, Renedo M, Fernández-Ruiz E, Peñalva 
MA, Rodríguez de Córdoba S. The molecular 
basis of alkaptonuria. Nat Genet 1996; 14:19-
24; PMID:8782815; http://dx.doi.org/10.1038/
ng0996-19
23. Fisher AA, Davis MW. Alkaptonuric ochronosis 
with aortic valve and joint replacements and femoral 
fracture: a case report and literature review. Clin Med 
Res 2004; 2:209-15; PMID:15931360; http://dx.doi.
org/10.3121/cmr.2.4.209
24. O’Brien WM, La Du BN, Bunim JJ. Biochemical, 
pathologic and clinical aspects of alkaptonuria, 
ochronosis and ochronotic arthropathy. 
Am J Med 1963; 34:813-38; http://dx.doi.
org/10.1016/0002-9343(63)90089-5
25. Manoj Kumar RV, Rajasekaran S. Spontaneous 
tendon ruptures in alkaptonuria. J Bone Joint Surg Br 
2003; 85:883-6; PMID:12931812
26. Introne WJ, Phornphutkul C, Bernardini 
I, McLaughlin K, Fitzpatrick D, Gahl WA. 
Exacerbation of the ochronosis of alkaptonuria due 
to renal insufficiency and improvement after renal 
transplantation. Mol Genet Metab 2002; 77:136-
42; PMID:12359141; http://dx.doi.org/10.1016/
S1096-7192(02)00121-X
27. Krízek V. Urolithiasis and prostatolithiasis in 
alcaptonuria with ochronosis. Int Urol Nephrol 
1971; 3:245-50; PMID:5154571; http://dx.doi.
org/10.1007/BF02081762
28. Gaines JJ Jr., Tom GD, Khankhanian N. An 
ultrastructural and light microscopic study of the 
synovium in ochronotic arthropathy. Hum Pathol 
1987; 18:1160-4; PMID:3679190; http://dx.doi.
org/10.1016/S0046-8177(87)80385-4
29. Reginato AJ, Schumacher HR, Martinez VA. 
Ochronotic arthropathy with calcium pyrophosphate 
crystal deposition. A light and electron microscopic 
study. Arthritis Rheum 1973; 16:705-14; 
PMID:4757869; http://dx.doi.org/10.1002/
art.1780160602
30. McClure J, Smith PS, Gramp AA. Calcium 
pyrophosphate dihydrate (CPPD) deposition in 
ochronotic arthropathy. J Clin Pathol 1983; 36:894-
902; PMID:6308064; http://dx.doi.org/10.1136/
jcp.36.8.894
31. Milch RA. Biochemical studies on the pathogenesis 
of collagen tissue changes in alcaptonuria. Clin 
Orthop 1962; 24:213-29; PMID:14473824
32. Perry MB, Suwannarat P, Furst GP, Gahl WA, 
Gerber LH. Musculoskeletal findings and disability 
in alkaptonuria. J Rheumatol 2006; 33:2280-5; 
PMID:16981292
33. Stenn FF, Milgram JW, Lee SL, Weigand RJ, Veis 
A. Biochemical identification of homogentisic acid 
pigment in an ochronotic egyptian mummy. Science 
1977; 197:566-8; PMID:327549; http://dx.doi.
org/10.1126/science.327549
34. Virchow R. Ein Fall von allgemeiner Ochronose der 
Knorpel und knorpelahnlichen Theile. Arch Path 
Anat 1866; 37:212-9
35. Wolkow M, Baumann E. Ueber das Wesen der 
Alkaptonurie. Z Phys Chem 1891; 15:228-85
36. Scriver CR. Garrod’s Croonian Lectures (1908) and 
the charter ‘Inborn Errors of Metabolism’: albinism, 
alkaptonuria, cystinuria, and pentosuria at age 
100 in 2008. J Inherit Metab Dis 2008; 31:580-
98; PMID:18850300; http://dx.doi.org/10.1007/
s10545-008-0984-9
37. La Du BN, Zannoni VG, Laster L, Seegmiller JE. 
The nature of the defect in tyrosine metabolism 
in alcaptonuria. J Biol Chem 1958; 230:251-60; 
PMID:13502394
38. Pollak MR, Chou YH, Cerda JJ, Steinmann B, La 
Du BN, Seidman JG, Seidman CE. Homozygosity 
mapping of the gene for alkaptonuria to chromosome 
3q2. Nat Genet 1993; 5:201-4; PMID:8252048; 
http://dx.doi.org/10.1038/ng1093-201
39. Sealock RR, Gladstone M, Steele JM. Administration 
of ascorbic acid to an alkaptonuric patient. Proc 
Soc Exp Biol Med 1940; 44:580-3; http://dx.doi.
org/10.3181/00379727-44-11534
40. Lorenzini S, Mannoni A, Selvi E. Alkaptonuria. 
N Engl J Med 2003; 348:1408, author reply 1408; 
PMID:12672874; http://dx.doi.org/10.1056/
NEJM200304033481421
41. Forslind K, Wollheim FA, Akesson B, Rydholm 
U. Alkaptonuria and ochronosis in three siblings. 
Ascorbic acid treatment monitored by urinary HGA 
excretion. Clin Exp Rheumatol 1988; 6:289-92; 
PMID:3180550
www.landesbioscience.com rare Diseases 7
42. Wolff JA, Barshop B, Nyhan WL, Leslie J, 
Seegmiller JE, Gruber H, Garst M, Winter S, 
Michals K, Matalon R. Effects of ascorbic acid in 
alkaptonuria: alterations in benzoquinone acetic 
acid and an ontogenic effect in infancy. Pediatr Res 
1989; 26:140-4; PMID:2771520; http://dx.doi.
org/10.1203/00006450-198908000-00015
43. de Haas V, Carbasius Weber EC, de Klerk JB, Bakker 
HD, Smit GP, Huijbers WA, Duran M, Poll-The 
BT. The success of dietary protein restriction in 
alkaptonuria patients is age-dependent. J Inherit 
Metab Dis 1998; 21:791-8; PMID:9870204; http://
dx.doi.org/10.1023/A:1005410416482
44. Ranganath LR, Jarvis JC, Gallagher JA. Recent 
advances in management of alkaptonuria (invited 
review; best practice article). J Clin Pathol 2013; 
66:367-73; PMID:23486607; http://dx.doi.
org/10.1136/jclinpath-2012-200877
45. Kobak AC, Oder G, Kobak S, Argin M, Inal 
V. Ochronotic arthropathy: disappearance of 
alkaptonuria after liver transplantation for hepatitis 
B-related cirrhosis. J Clin Rheumatol 2005; 11:323-
5; PMID:16371803; http://dx.doi.org/10.1097/01.
rhu.0000191157.25894.55
46. Alkaptonuria Society [Internet]. Cambridge (UK): 
Alkaptonuria Society Ltd; c2012 [cited 15 May 
2013]. Available from: http://www.akusociety.org/
index.html
47. Introne WJPM, Perry MB, Troendle J, Tsilou E, 
Kayser MA, Suwannarat P, O’Brien KE, Bryant J, 
Sachdev V, Reynolds JC, et al. A 3-year randomized 
therapeutic trial of nitisinone in alkaptonuria. Mol 
Genet Metab 2011; 103:307-14; PMID:21620748; 
http://dx.doi.org/10.1016/j.ymgme.2011.04.016
48.  Preston AJ, Keenan CM, Sutherland H, Wilson PJ, 
Wlodarski B, Taylor AM, Williams DP, Ranganath 
LR, Gallagher JA, Jarvis JC. Ochronotic osteo-
arthropathy in a mouse model of alkaptonuria, 
and its inhibition by nitisinone. Ann Rheum Dis 
2014; 73:284-9; PMID:23511227; http://dx.doi.
org/10.1136/annrheumdis-2012-202878
49. Medscape Reference Nitisinone (Rx) - Orfadin; adverse 
effects [Internet]. New York (NY): Medscape, 
LLC; c2014 [cited 15 May 2013]. Available 
from: http://reference.medscape.com/drug/
orfadin-nitisinone-342859#4
50. Ellaway CJ, Holme E, Standing S, Preece MA, Green 
A, Ploechl E, Ugarte M, Trefz FK, Leonard JV. 
Outcome of tyrosinaemia type III. J Inherit Metab 
Dis 2001; 24:824-32; PMID:11916315; http://
dx.doi.org/10.1023/A:1013936107064
51. Taylor AM. An investigation of the pathogenesis of 
ochronosis in Alkaptonuria (AKU) [dissertation]. 
Liverpool: University of Liverpool, 2011.
52. Johnson EH, Miller RL. Alkaptonuria in a 
cynomolgus monkey (Macaca fascicularis). J Med 
Primatol 1993; 22:428-30; PMID:8169945
53. Watkins SP, Benley H, Shulman NR. 2nd conference 
on experimental medicine and surgery in primates, 
New York NY. September 1969. Medical primatology 
1970.: Basel: Karger.
54. Keeling ME, McClure HM, Kibler RF. Alkaptonuria 
in an orangutan (Pongo pygmaeus). Am J Phys 
Anthropol 1973; 38:435-8; PMID:4689767; http://
dx.doi.org/10.1002/ajpa.1330380245
55. Lonsdale D. Why I left orthodox medicine: Healing 
for the 21st century. Charlottesville, VA: Hampton 
Roads Publishing Company, 1994.
56. Lewis JH. Alcaptonuria in a rabbit. J Biol Chem 
1926; 70:659
57. Moran TJ, Yunis EJ. Studies on ochronosis. 2. Effects 
of injection of homogentisic acid and ochronotic 
pigment in experimental animals. Am J Pathol 1962; 
40:359-69; PMID:14475795
58. Blivaiss BB, Rosenberg EF, Kutuzov H, Stoner R. 
Experimental ochronosis. Induction in rats by long-
term feeding with L-tyrosine. Arch Pathol 1966; 
82:45-53; PMID:5938449
59. Montagutelli X, Lalouette A, Coudé M, Kamoun 
P, Forest M, Guénet JL. aku, a mutation of the 
mouse homologous to human alkaptonuria, 
maps to chromosome 16. Genomics 1994; 19:9-
11; PMID:8188247; http://dx.doi.org/10.1006/
geno.1994.1004
60. Manning K, Fernández-Cañón JM, Montagutelli 
X, Grompe M. Identification of the mutation 
in the alkaptonuria mouse model. Mutations in 
brief no. 216. Online. Hum Mutat 1999; 13:171; 
PMID:10094559; http://dx.doi.org/10.1002/
( S I C I ) 10 9 8 -10 0 4 ( 19 9 9 ) 1 3 : 2 < 17 1 : : A I D -
HUMU15>3.0.CO;2-W
61. Suzuki Y, Oda K, Yoshikawa Y, Maeda Y, Suzuki T. 
A novel therapeutic trial of homogentisic aciduria 
in a murine model of alkaptonuria. J Hum Genet 
1999; 44:79-84; PMID:10083729; http://dx.doi.
org/10.1007/s100380050114
62. Taylor AM, Preston AJ, Paulk NK, Sutherland H, 
Keenan CM, Wilson PJ, Wlodarski B, Grompe M, 
Ranganath LR, Gallagher JA, et al. Ochronosis in a 
murine model of alkaptonuria is synonymous to that 
in the human condition. Osteoarthritis Cartilage 
2012; 20:880-6; PMID:22542924; http://dx.doi.
org/10.1016/j.joca.2012.04.013
63. Hayami T, Pickarski M, Wesolowski GA, McLane J, 
Bone A, Destefano J, Rodan GA, Duong T. The role 
of subchondral bone remodeling in osteoarthritis: 
reduction of cartilage degeneration and prevention of 
osteophyte formation by alendronate in the rat anterior 
cruciate ligament transection model. Arthritis Rheum 
2004; 50:1193-206; PMID:15077302; http://dx.doi.
org/10.1002/art.20124
64. Castañeda S, Roman-Blas JA, Largo R, Herrero-
Beaumont G. Subchondral bone as a key target 
for osteoarthritis treatment. Biochem Pharmacol 
2012; 83:315-23; PMID:21964345; http://dx.doi.
org/10.1016/j.bcp.2011.09.018
65. Karsdal MA, Leeming DJ, Dam EB, Henriksen 
K, Alexandersen P, Pastoureau P, Altman RD, 
Christiansen C. Should subchondral bone turnover be 
targeted when treating osteoarthritis? Osteoarthritis 
Cartilage 2008; 16:638-46; PMID:18362080; 
http://dx.doi.org/10.1016/j.joca.2008.01.014
66. Bálint G, Szebenyi B. Hereditary disorders mimicking 
and/or causing premature osteoarthritis. Baillieres 
Best Pract Res Clin Rheumatol 2000; 14:219-
50; PMID:10925743; http://dx.doi.org/10.1053/
berh.2000.0063
67. Lagier R. Ochronotic arthropathy, an approach to 
osteoarthritis bone remodelling. Rheumatol Int 
2006; 26:561-4; PMID:16435121; http://dx.doi.
org/10.1007/s00296-005-0087-y
68. van Lierop AH, Hamdy NAT, van Bezooijen RL, 
Lowik CW, Papapoulos SE. The role of sclerostin 
in the pathophysiology of sclerosing bone dysplasias. 
Clinical Reviews in Bone and Mineral Metabolism 
2012; 10:108; http://dx.doi.org/10.1007/
s12018-011-9123-5
69. Moester MJC, Papapoulos SE, Löwik CW, van 
Bezooijen RL. Sclerostin: current knowledge and 
future perspectives. Calcif Tissue Int 2010; 87:99-
107; PMID:20473488; http://dx.doi.org/10.1007/
s00223-010-9372-1
